{"doi":"10.1002/pbc.28502","title":"A single‐arm study of systemic and sub‐Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231)","abstract":"BACKGROUND: Eyes with Group D intraocular retinoblastoma have low salvage rates. A pilot study showed safety and efficacy of sub-Tenon's fascia carboplatin with systemic chemotherapy supporting further study. METHODS: Children with newly diagnosed bilateral intraocular retinoblastoma with at least one remaining Group C or D eye were treated with six courses of carboplatin/etoposide/vincristine (CEV) with sub-Tenon's fascia carboplatin for Group C/D eyes during courses 2-4. Local ophthalmic therapy started at course 3. The primary study objective was to determine the 1-year failure rate of Group D eyes. RESULTS: The study closed prematurely due to poor accrual and 22 of 30 patients were evaluable for failure rate, contributing 25 Group D and four Group C eyes. Among the 25 Group D eyes, there were 13 failures within the first year of study enrollment including eight needing external beam radiotherapy (EBR) and five needing enucleation, resulting in 1-year failure rate of 52%. The failure rate was significantly lower than the historical rate of 70% (P = .039). The 1-year eye preservation rate for Group D eyes was 80% (20/25). One-year failure rate for Group C eyes was 25% (1/4); 1-year preservation rate was 100% without need for EBR. Systemic toxicity included Grade 3 hearing loss in two subjects, infections, neutropenia, and thrombocytopenia. Ocular toxicities included periorbital fat atrophy (13/29 = 45% eyes), optic nerve atrophy (1/29 = 3% eyes), and restrictive fibrosis (1/29 = 3% eyes). CONCLUSIONS: Sub-Tenon's fascia carboplatin plus CEV was partially effective in Group D intraocular retinoblastoma but had unacceptable ocular toxicities.","journal":"Pediatric Blood & Cancer","year":2020,"id":79542,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9557,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":413359,"name":"Judith G. Villablanca","orcid":"0000-0002-7174-669X","position":1,"is_corresponding":false},{"id":413360,"name":"Mark Krailo","orcid":"0000-0002-7608-0698","position":2,"is_corresponding":false},{"id":413361,"name":"Jin Piao","orcid":"0000-0003-0516-6280","position":3,"is_corresponding":false},{"id":413362,"name":"Li Huang","orcid":"0000-0003-1432-2054","position":4,"is_corresponding":false},{"id":414753,"name":"A. Linn Murphree","orcid":null,"position":5,"is_corresponding":false},{"id":291481,"name":"Joan M. O’Brien","orcid":"0000-0003-4109-2928","position":6,"is_corresponding":false},{"id":320446,"name":"Dan S. Gombos","orcid":"0000-0003-2867-6320","position":7,"is_corresponding":false},{"id":413363,"name":"Carol L. Shields","orcid":"0000-0002-3288-3632","position":8,"is_corresponding":false},{"id":414754,"name":"Anna T. Meadows","orcid":null,"position":9,"is_corresponding":false},{"id":342733,"name":"Murali Chintagumpala","orcid":"0000-0003-2686-6737","position":10,"is_corresponding":false},{"id":317492,"name":"Rima Jubran","orcid":"0000-0002-2169-7826","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-18T21:50:57.971597Z","pmid":"32589362","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}